Your session is about to expire
← Back to Search
CAR T-cell Therapy
JCAR017 for Chronic Leukemia or Lymphoma
Phase 1 & 2
Recruiting
Research Sponsored by Juno Therapeutics, a Subsidiary of Celgene
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Confirmation of CD19-positive disease if prior CD19-targeted therapy has been administered
Diagnosis of SLL with lymphadenopathy and/or splenomegaly and < 5×10^9 CD19+ CD5+ clonal B lymphocytes/L [< 5000/µL] in the peripheral blood at diagnosis with measurable disease that is biopsy-proven SLL
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 48 months post treatment
Awards & highlights
Study Summary
This trial is testing a new drug, JCAR017, to see if it is safe and effective at treating leukemia in adults. The trial will be conducted in two parts, with a separate cohort testing the drug in combination with ibrutinib or venetoclax. All subjects will be monitored for safety and efficacy, and the pharmacokinetics of JCAR017 will be studied.
Who is the study for?
Adults with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) who have failed multiple prior therapies can join. Participants must have adequate organ and bone marrow function, not be pregnant, and cannot have active infections like hepatitis B/C or HIV.Check my eligibility
What is being tested?
The trial is testing JCAR017 alone or in combination with either ibrutinib or venetoclax to treat CLL/SLL. It's a multi-phase study starting with finding the right dose of JCAR017 before moving on to test its effectiveness and safety at that dose.See study design
What are the potential side effects?
Potential side effects include reactions related to gene therapy, infection risks due to weakened immune system, liver problems, kidney issues, breathing difficulties, heart complications from chemotherapy drugs used alongside JCAR017.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer is CD19 positive, even after CD19-targeted treatment.
Select...
I have SLL with specific symptoms and a certain level of B lymphocytes.
Select...
I have tried and not responded to BTK inhibitor treatment or was deemed ineligible for it.
Select...
I am fully active and can carry on all my pre-disease activities without restriction.
Select...
I am suitable for or already have a central or peripheral line for blood filtering procedures.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 48 months post treatment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 48 months post treatment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: adverse events
Phase 1 JCAR017 and ibrutinib combination dose escalation therapy arm: laboratory abnormalities
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm
+6 moreSecondary outcome measures
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of complete response (DoCR)
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: Duration of response (DOR)
Phase 1 JCAR017 and ibrutinib combination dose expansion therapy arm: MRD negative response rate in peripheral blood
+34 moreTrial Design
4Treatment groups
Experimental Treatment
Group I: Phase 2 JCAR017 monotherapyExperimental Treatment1 Intervention
Subjects will receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm
Group II: Phase 1 JCAR017 monotherapyExperimental Treatment1 Intervention
Subjects will be assigned to receive JCAR017 (lisocabtagene maraleucel)
Group III: Phase 1 JCAR017 + venetoclaxExperimental Treatment2 Interventions
Subjects will receive venetoclax as bridging anticancer therapy until lymphodepletion chemotherapy/ JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm. After JCAR017 infusion subjects will receive venetoclax until Day 90.
Group IV: Phase 1 JCAR017 + ibrutinibExperimental Treatment1 Intervention
Subjects receiving ibrutinib at baseline will be assigned to receive JCAR017 (lisocabtagene maraleucel) at the recommended dose from the Phase 1 monotherapy arm + ibrutinib
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Chimeric Antigen Receptor (CAR) T-cell therapy is a cutting-edge treatment for lymphoma that involves modifying a patient's own T-cells to express receptors specific to cancer cells. These engineered T-cells are then infused back into the patient, where they can recognize and attack lymphoma cells.
This therapy is significant for lymphoma patients because it offers a targeted approach that can lead to durable remissions, especially in cases where the disease is refractory or has relapsed after conventional treatments. The ability of CAR T-cells to specifically target and destroy cancer cells while sparing normal cells represents a major advancement in lymphoma treatment.
Find a Location
Who is running the clinical trial?
Juno Therapeutics, a Subsidiary of CelgeneLead Sponsor
11 Previous Clinical Trials
1,185 Total Patients Enrolled
5 Trials studying Lymphoma
593 Patients Enrolled for Lymphoma
Heidi Gillenwater, MDStudy DirectorJuno Therapeutics, Inc.
3 Previous Clinical Trials
341 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,520 Previous Clinical Trials
3,371,538 Total Patients Enrolled
55 Trials studying Lymphoma
10,418 Patients Enrolled for Lymphoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am eligible for a therapy combining ibrutinib and JCAR017.My condition has progressed to Richter's transformation.I am experiencing severe symptoms from a transplant rejection.I have a significant brain or nervous system condition.My cancer is CD19 positive, even after CD19-targeted treatment.My cancer has spread into blood vessels.I have unmanaged blood clots in my veins.I am not taking any strong medication that affects liver enzymes with my current cancer treatment.I have been diagnosed with CLL and need treatment according to my doctor.I have SLL with specific symptoms and a certain level of B lymphocytes.I have tried and not responded to BTK inhibitor treatment or was deemed ineligible for it.I have had another type of cancer in the last 2 years.My kidneys, liver, lungs, and heart are functioning well.I am eligible for specific drug combination treatments.My cancer has spread to my brain or spinal cord.I have received gene therapy before.I have had heart problems in the last 6 months.I do not have active hepatitis B, C, or HIV.My bone marrow is healthy enough for strong chemotherapy.I haven't taken certain medications before my leukapheresis.I am fully active and can carry on all my pre-disease activities without restriction.I have received previous treatment, but not in the ibrutinib + JCAR017 combination.I am suitable for or already have a central or peripheral line for blood filtering procedures.I do not have any untreated infections.
Research Study Groups:
This trial has the following groups:- Group 1: Phase 1 JCAR017 + ibrutinib
- Group 2: Phase 1 JCAR017 + venetoclax
- Group 3: Phase 2 JCAR017 monotherapy
- Group 4: Phase 1 JCAR017 monotherapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger